Boai Nky Pharmaceuticals Stock Current Valuation
| 300109 Stock | 14.79 0.19 1.27% |
Valuation analysis of Boai NKY Pharmaceuticals helps investors to measure Boai NKY's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Boai NKY's Free Cash Flow is projected to increase significantly based on the last few years of reporting. The current year's Begin Period Cash Flow is expected to grow to about 517.6 M, whereas Cash is forecasted to decline to about 259.9 M. Fundamental drivers impacting Boai NKY's valuation include:
Price Book 2.0708 | Enterprise Value 7.3 B | Enterprise Value Ebitda 17.0655 | Price Sales 4.8897 | Trailing PE 18.962 |
Overvalued
Today
Please note that Boai NKY's price fluctuation is somewhat reliable at this time. Calculation of the real value of Boai NKY Pharmaceuticals is based on 3 months time horizon. Increasing Boai NKY's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Boai NKY is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Boai Stock. However, Boai NKY's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 14.79 | Real 11.59 | Hype 14.85 | Naive 14.57 |
The real value of Boai Stock, also known as its intrinsic value, is the underlying worth of Boai NKY Pharmaceuticals Company, which is reflected in its stock price. It is based on Boai NKY's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Boai NKY's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Boai NKY Pharmaceuticals helps investors to forecast how Boai stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Boai NKY more accurately as focusing exclusively on Boai NKY's fundamentals will not take into account other important factors: Boai NKY Pharmaceuticals Company Current Valuation Analysis
Boai NKY's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Boai NKY Current Valuation | 7.34 B |
Most of Boai NKY's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Boai NKY Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Boai NKY Pharmaceuticals has a Current Valuation of 7.34 B. This is 48.87% lower than that of the Chemicals sector and significantly higher than that of the Materials industry. The current valuation for all China stocks is 55.82% higher than that of the company.
Boai Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Boai NKY's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Boai NKY could also be used in its relative valuation, which is a method of valuing Boai NKY by comparing valuation metrics of similar companies.Boai NKY is currently under evaluation in current valuation category among its peers.
Boai Fundamentals
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0651 | ||||
| Profit Margin | 0.27 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 7.34 B | ||||
| Shares Outstanding | 484.7 M | ||||
| Shares Owned By Insiders | 24.98 % | ||||
| Shares Owned By Institutions | 5.90 % | ||||
| Price To Book | 2.07 X | ||||
| Price To Sales | 4.89 X | ||||
| Revenue | 1.59 B | ||||
| Gross Profit | 690.63 M | ||||
| EBITDA | 671.45 M | ||||
| Net Income | 485.79 M | ||||
| Total Debt | 60.41 M | ||||
| Book Value Per Share | 7.23 X | ||||
| Cash Flow From Operations | 488.25 M | ||||
| Earnings Per Share | 0.79 X | ||||
| Target Price | 26.15 | ||||
| Number Of Employees | 1.17 K | ||||
| Beta | 0.12 | ||||
| Market Capitalization | 7.26 B | ||||
| Total Asset | 4.02 B | ||||
| Retained Earnings | 1.01 B | ||||
| Working Capital | 760.05 M | ||||
| Annual Yield | 0.07 % | ||||
| Net Asset | 4.02 B | ||||
| Last Dividend Paid | 0.67 |
About Boai NKY Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Boai NKY Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Boai NKY using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Boai NKY Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Boai Stock
Boai NKY financial ratios help investors to determine whether Boai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Boai with respect to the benefits of owning Boai NKY security.